Skip to main content
English
▾
Accessibility
Off
News
Community
The
State
of Israel
Sign in
News
Community
English
▾
Sign in
Contact
Aug 5
InMode Holds Quarterly Revenue at $95.6 Million and Reaffirms 2026 Outlook
More
Selected story
Aug 5
Silexion Reports Three-Pathway Immune Sensitization in SIL204 Cancer Study
More
Aug 5
NeuroThera Launches Yale Phase IIb Trial for Tourette Syndrome Treatment
More
Show all connections (2)
Share
Silexion Reports Three-Pathway Immune Sensitization in SIL204 Cancer Study
News
Socials
Menu
Swipe Mode
You
Something went wrong
We couldn't complete that action. Check your connection and try again.
Close
